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ScienceDirectManipulating cytokine function with protein-based drugs has
proven effective for treating a wide variety of autoimmune and
autoinflammatory disorders. However, the limited ability of
protein-based drugs to modulate intracellular targets, including
many implicated by studies of the genetics and physiology of
these diseases, and to coordinately neutralize redundant
inflammatory cytokines, suggests an important and
complementary role for small molecules in immunomodulatory
drug development. The recent clinical approval of Janus kinase
and phosphodiesterase inhibitors, along with emerging
evidence from other compound classes, firmly establish small
molecules as effective tools for modulating therapeutically
relevant proteins that give rise to aberrant cytokine signaling or
mediate its downstream consequences.
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Introduction
The incidence of autoimmune and autoinflammatory dis-
orders is rapidly increasing in developed countries [1].
Addressing this clinical need will require continued
innovation in immunomodulatory drug development.
Data from many sources, including analysis of how
human genetic variation affects disease susceptibility,
implicate aberrant cytokine production and signaling
in the pathophysiology of these disorders (see Box 1 forwww.sciencedirect.com background on the application of disease genetics to
drug discovery). For example, mutations in the cellular
machinery that processes the inflammatory cytokine
interleukin-1b (IL-1b) to its mature form cause hereditary
autoinflammatory diseases known as cryopyrin disorders
(Figure 1a) [2]. Protein therapies inhibiting IL-1b
(canakinumab; rilonacept) or its receptor (anakinra) are
used to treat cryopyrin disorders, as well as immune
disorders with more complex etiologies, including gout,
type-2 diabetes, rheumatoid arthritis (RA) and chronic
granulomatous disease [3,4]. The clinical success of
biopharmaceuticals targeting IL-1b or other cytokines
(TNF-a, IL-6, IL-12/23) derives from their ability to
disrupt protein–protein interactions with exquisite selec-
tivity and predictable, long-lasting pharmacology [5].
Despite this success, several limitations of biopharma-
ceuticals hamper therapeutic manipulation of cytokine
networks. Most notably, protein-based therapies are
unable to regulate intracellular proteins, including many
potential targets identified by disease genetics and
recent studies of mechanisms that regulate immune cell
development and function, for example, using high-
throughput transcriptional profiling [6–10]. Also, while
systemic administration of blocking antibodies or decoy
receptors can effectively neutralize individual cytokines in
circulation, these effects can be undermined by functional
redundancy among inflammatory cytokines or limited
delivery of protein-based reagents to mucosal tissues
[5,11]. Finally, biopharmaceuticals are expensive to
produce and lack oral availability, which often necessitates
administration by specialists.
Small molecules constitute a complementary approach to
immunomodulatory drug development by enabling
modulation of intracellular proteins that give rise to
aberrant cytokine signaling or mediate its downstream
consequences. Endogenous small molecules such as
eicosanoids have long been recognized to play a key role
in controlling tissue-specific inflammation [12], and the
impact of metabolites made by commensal microbes on
cytokine-producing cells is increasingly clear [13–15].
Moreover, drugs modulating intracellular signaling
proteins (rapamycin targeting mTOR [16]; FK506 and
cyclosporine A targeting calcineurin [17]) were among
the first immunomodulatory therapies approved by the
FDA. More recently, small molecules have been discov-
ered that modulate cytokine function through a range
of mechanisms-of-action (Table 1). These successesCurrent Opinion in Chemical Biology 2014, 23:23–30
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Box 1 Using human disease genetics to guide drug
development.
The study of human genetics can uncover factors that contribute to
the initiation and maintenance of disease, and suggest new
strategies for therapeutic intervention. Therapies directed at
correcting defects associated with causative alleles in Mendelian
disease — protein therapeutics targeting IL-1b in cyropyrin disorders
(see main text) or the small molecule ivacaftor to modulate the
mutant CFTR-G551D protein linked to cystic fibrosis — illustrate the
potential of genetics to inform discovery of effective medicines
[2,61]. In contrast to Mendelian diseases, many autoimmune/
autoinflammatory diseases have a complex genetic architecture in
which susceptibility is influenced by multiple alleles as well as
environmental factors. For instance, a recent genome-wide asso-
ciation study of inflammatory bowel disease (IBD) identified single
nucleotide polymorphisms (SNPs) in 163 genetic loci (i.e., chromo-
somal regions) associated with altered disease risk [23]. Leveraging
these insights for drug discovery will require understanding how
disease genes contribute to pathophysiology [62]. For example, the
ATG16L1-T300A SNP that confers increased risk of Crohn’s disease
(CD) is associated with defects in bacteria clearance and inflam-
matory cytokine production [63,64]. Small molecules that correct
these defects may be useful for treating CD [65]. While potentially
less straightforward than monogenic diseases, the fact that several
FDA-approved drugs have been shown retrospectively to modulate
genes with risk-associated polymorphisms (e.g. thiazolidinediones
targeting PPARg for treatment of type 2 diabetes) and the early
evidence of success for emerging targets (e.g., PCSK9 in cardio-
vascular disease) suggests the approach may extend to complex
inherited diseases (reviewed in [66]).establish small molecules as a complementary alternative
to protein-based therapies for regulating cytokine net-
works. Here, we review recent findings that motivate
discovery of small molecules targeting kinases, other
classes of signaling proteins, as well as transcriptional
regulators implicated in aberrant cytokine signaling by
the genetics and physiology of autoimmune/autoinflam-
matory disorders.
Regulation of immune cell signaling with
kinase inhibitors
Small molecules have been used successfully to manip-
ulate immune cell signaling at several levels. Prostanoid
receptor agonists are being explored as IBD therapies
[12], whereas pathogen receptor agonists (imiquimod) are
used clinically to treat skin disorders [18]. Phosphodi-
esterase-4 (PDE4) inhibitors such as apremilast, approved
for treatment of psoriatic arthritis, demonstrate the utility
of modulating intracellular targets within cytokine sig-
naling networks. Given the central role of kinases in
cellular networks that control cytokine production and
signaling, it is likely that novel kinase inhibitors will be
important for treating autoimmune/autoinflammatory
disorders going forward [19].
Although inhibitors of protein kinases have been devel-
oped largely for neoplastic disorders in recent years, the
first drug of this class (rapamycin) initially obtained FDA
approval for use as an immunosuppressant followingCurrent Opinion in Chemical Biology 2014, 23:23–30 organ transplantation. Rapamycin forms a ternary com-
plex with FKBP12 and mTOR resulting in an immune
cell state reminiscent of nutrient starvation [20]. A
consequence is suppression of T and B cell responses
normally elicited by activation of antigen receptor and/or
IL-2 signaling. This seminal example illustrates the abil-
ity of kinase modulators to disrupt coordinately multiple
signals needed for lymphocyte activation. The more
recent approval of the Janus kinase-3 (JAK3) inhibitor
tofacitinib for treatment of RA illustrates how small
molecules can target redundancies within cytokine sig-
naling networks. JAK3 preferentially associates with the
common gamma chain (gc), which is a shared component
of the receptor for IL-2 and many other cytokines
(Figure 1b) [21]. Blocking gc/JAK3 signaling with
tofacitinib affects several immune processes including
reducing survival of activated T cells [22].
In addition to suppressing inflammatory cytokine func-
tion, kinase inhibitors may be exploited to stimulate
production of anti-inflammatory cytokines such as IL-10.
The importance of the IL-10 pathway in IBD is evidenced
by disease-associated polymorphisms near IL10 and its
receptor (IL10RA), as well as near genes that control its
production, such as PTGER4 (which encodes the EP4
prostanoid receptor) and the transcriptional co-activator
CRTC3 [23]. Salt-inducible kinase 2 (SIK2) normally
suppresses IL-10 production by phosphorylation of
CRTC3 (CREB-regulated transcriptional co-activator 3),
which results in its cytosolic sequestration by 14-3-3
proteins (Figure 1c) [24,25]. Stimuli that enhance cAMP
levels (e.g., prostaglandin E2 or PDE4 inhibitors) suppress
SIK2 activity and robustly potentiate IL-10 production by
macrophages and dendritic cells (DCs), a phenotype that
can be mimicked by small molecules that directly inhibit
SIK2 [24,25,26]. Whereas recombinant IL-10 supple-
mentation is ineffective in Crohn’s disease (CD) patients
[27], perhaps due to insufficient delivery to the gut mucosa
[28], these data suggest that SIK2 inhibition may be
effective at increasing IL-10 levels directly in this tissue.
The additional ability of SIK2 inhibitors to suppress
production of IL-12 and other inflammatory cytokines
makes this kinase a promising target for further investi-
gation in IBD [24,26].
Studies from genetics, physiology and chemical biology
continue to implicate kinases as potential targets for restor-
ing normal cytokine function in disease (Table 1). Novel
polymorphisms in leucine-rich repeat kinase 2 (LRRK2, a
gene previously linked to Parkinson’s disease) confer
increased risk of IBD [29]. Functional studies suggest that
LRRK2 regulates production of reactive oxygen species
and inflammatory cytokines by macrophages [30,31]. In
addition, SNPs near IRAK1, which encodes a kinase
required for production of interferons (IFNs) following
viral infection, confer increased risk of systemic lupus
erythematosus [32]. The serum/glucocorticoid-regulatedwww.sciencedirect.com
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Representative pathways regulating cytokine production and signaling that have been targeted by small molecules. (A) Microbial stimulation of innate
immune cells induces transcription of full-length IL-1b and IL-18. Additional stress signals trigger inflammasome assembly leading to proteolytic
processing of IL-1b and IL-18 to their mature forms by caspase-1. VX-765 and other caspase-1 inhibitors specifically block the final stage in this
process. NLRP3, NOD-like receptor family, pyrin domain containing 3; ASC, apoptosis-associated speck-like protein containing a carboxy-terminal
CARD. (B) The common gamma chain (gc) is a shared component of the receptor for IL-2 and many cytokines and preferentially associates with Janus
kinase-3 (JAK3). Stimulation of gc triggers JAK3-dependent phosphorylation of STAT family transcription factors, which leads to pleiotropic effects on
immune cell function. Suppression of gc signaling with the small-molecule JAK3 inhibitor tofacitinib is approved therapy for rheumatoid arthritis. STAT,
signal transducer and activator of transcription. (C) Salt-inducible kinases (SIKs) restrain IL-10 production by phosphorylation of CRTC3 (CREB-
regulated transcriptional co-activator 3), which results in its cytosolic sequestration by 14-3-3 proteins. Stimuli that elevate intracellular cAMP levels
(e.g., prostaglandin E2 or PDE4 inhibitors) suppress SIK activity and robustly potentiate IL-10 production by macrophages and dendritic cells, a
phenotype that can be mimicked by small molecules that directly inhibit SIKs such as HG-9-91-01, dasatinib, and bosutinib. PKA, protein kinase A. (D)
Differentiation of inflammatory TH17 cells requires the activity of the transcription factor RORgt and the chromatin-binding BET proteins. Small
molecules that inhibit RORgt or prevent BET protein binding to acetylated substrates suppress differentiation of TH17 cells.kinase 1 (SGK1) regulates differentiation of TH17 cells, a
CD4+ T cell subset that produces IL-17A and other
inflammatory cytokines, in response to environmental
factors including NaCl; small-molecule inhibition of
SGK1 suppresses high salt-induced TH17 development
[33,34]. Mechanism-of-action studies have implicated
the phoshatidylinositol kinase PIKfyve as the target ofwww.sciencedirect.com the clinical candidate apilimod, an inhibitor of IL-12/23
production discovered through phenotypic screening
[35,36]. Targeting kinases implicated in cytokine regula-
tion, with novel inhibitors or those repurposed from
other indications, is a critical step for testing novel thera-
peutic hypotheses and may yield valuable starting points
for drug development.Current Opinion in Chemical Biology 2014, 23:23–30
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Table 1
Examples of small-molecule modulators of cytokine function.
Target protein Small molecule Effects of target
modulation on immune
cell function
Clinical status
Kinases and phosphatases
mTOR Rapamycin [16] Inhibits T and B cell activation; promotes Treg
differentiation [20]
Approved for suppression of
transplant rejection
Calcineurin Cyclosporine A; FK506 [17] Inhibits NFAT-mediated IL-2 production [17] Approved for suppression of
transplant rejection
JAK3 Tofacitinib [22] Inhibits cytokine via receptors using the
common gamma chain (gc) [21]
Approved for RA
SGK1 GSK650394 [67] Inhibits IL-17A production and other
phenotypes in salt-induced TH17 cells [33,34]
Pre-clinical
Lyp/PTPN22 LTV-1 [68] Potentiates T and B cell responses [68,69] Pre-clinical
PIKfyve Apilimod [36] Inhibits TLR-induced IL-12p40 production
[35,36]
Phase II for Crohn’s Disease;
Phase I for Psoriasis
SIK2 HG-9-91-01 [24]; Dasatinib,
Bosutinib [26]
Potentiates IL-10 production by activated
macrophages and DCs [24,25]
Pre-clinical
IRAK1 IRAK1/4inh [70] Inhibits virus-stimulated interferon
production [71]
Pre-clinical
LRRK2 GNE-7915 and others [72] Reducing LRRK2 protein levels suppresses
inflammatory cytokine production [30,31]
Pre-clinical
Chromatin modulators
HDACs TSA, SAHA and others [73] Inhibits inflammatory cytokine production;
increase Treg survival/function [74]
Pre-clinical
HDAC6 Tubastatin A [52] Potentiates IL-10 production by activated
macrophages [52]
Pre-clinical
JMJD3 and UTX GSK-J4 [48] Inhibits inflammatory cytokine production
[48]
Pre-clinical
BET proteins (+)-JQ1, I-BET762 and
others [54]
Inhibits inflammatory cytokine production
[55–57,75]
Pre-clinical; phase II for type
2 diabetes (I-BET762)
RORgt Digoxin, SR1001 and
others [42,43]
Inhibits TH17 cells differentiation [42,43
] Pre-clinical
AhR TCDD, kynurenines and
others [45,46]
Stimulates IL-10 production; promotes Treg
differentiation [45,46]
Pre-clinical
RAR ATRA and others [76] Promotes Treg differentiation; inhibits
TH17 cell differentiation [44]
Pre-clinical
Proteases
Caspase-1 VX-765 [77] Inhibits proteolytic processing of IL-1b and
IL-18 to secreted forms [78]
Phase I for Muckle-Wells
syndrome; Phase II for
psoriasis
Immuno-proteasome ONX 0914 and others [79] Inhibits antigen processing and inflammatory
cytokine production (IL-23; IFNg; IL-2) [80].
Pre-clinical
Regulators of second messengers
PDE4 Apremilast and others [24] Inhibits cAMP degradation, leading to
enhanced IL-10 production [81]
Approved for psoriatic arthritis
Receptors
Toll-like receptors Rintatolimod (TLR3) [82];
Imiquimod (TLR7) [83];
IMO-2125 (TLR9) [84]
Stimulates inflammatory cytokine production
(e.g. type I IFNs) [18].
Phase II for HIV infection
(Rintatolimod); Approved for
treatment of skin disorders
(imiquimod); phase I for
Hepatitis C (IMO-2125)
IL-2/IL-2R SP-4206 and others [85] Inhibits IL-2 binding to IL-2R [86] Pre-clinical
Prostanoid receptors EP4 selective agonists [12] Elevates intracellular cAMP levels, leading to
enhance IL-10 production [25]
Phase II for ulcerative colitisControlling inflammation by targeted
modulation of transcription
Signaling cascades downstream of immune receptors
converge on transcription factors to regulate cytokine
expression. The clinical success of calcineurin inhibitors,
which suppress IL-2 production following T cell receptorCurrent Opinion in Chemical Biology 2014, 23:23–30 stimulation by preventing dephosphorylation of NFAT
[17], demonstrates the utility of small molecules that
target transcriptional regulation in immune cells. In
addition to acute transcriptional responses, activation of
immune cells leads to chromatin modifications that can
promote acquisition of distinct effector states [6–9].www.sciencedirect.com
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and histone modifications with gene expression have
identified super-enhancers and other chromatin features
that regulate immune cell function [9,37,38,39]. These
insights, coupled with new tools for targeting transcrip-
tion factors and chromatin-modifying proteins (Table 1),
suggest that small-molecule modulators of transcription
will be useful for therapeutic manipulation of cytokine
networks.
RORgt (retinoid-related orphan receptor gt) is a nuclear
hormone receptor (NHR) implicated in CD by human
genetics that promotes differentiation of TH17 cells
(Figure 1d) [23,40]. Although a monoclonal antibody
targeting IL-17A (secukinumab) has demonstrated
potential for treating psoriasis and ankylosing spondylitis,
it is ineffective in CD patients [41]. The failure of IL-17A
blockade in CD may suggest the need to suppress a wider
set of cytokines produced by TH17 cells, possibly by
interfering with TH17 differentiation. RORgt contains
a deep binding pocket for endogenous small-molecule
ligands, which has facilitated development of RORgt
antagonists that suppress TH17 cell differentiation and
display efficacy in murine models of graft-versus-host
disease, demyelinating neurological disorders and
cutaneous inflammation [42,43].
Their established roles in immune cell function, coupled
with their ability to bind small molecules, make other
NHRs intriguing drug targets. Activation of the retinoic
acid receptor (RAR) by vitamin A metabolites enhances
development of anti-inflammatory CD4+ regulatory T
cells (Tregs), an effect that contributes to the therapeutic
activity of all-trans retinoic acid in murine models of
autoimmune disease [44]. Binding of the aryl hydro-
carbon receptor (AhR) by the tryptophan metabolite
kynurenine stimulates IL-10 production by DCs and
promotes Treg differentiation [45,46]; two mechanisms
that may underlie the finding that sub-lethal doses of
bacteria enhance resistance to subsequent infections [47].
NHRs often work in concert with chromatin-modifying
enzymes, several classes of which have been targeted
with small molecules to modulate cytokine production.
The novel small-molecule inhibitor of the Jumonji family
histone demethylases JMJD3 and UTX (GSK-J4)
suppresses inflammatory cytokine production in macro-
phages [48]. Histone deacetylase (HDAC) inhibitors
targeting multiple isoforms suppress inflammatory
cytokine production by macrophages, promote Treg
differentiation and display efficacy in murine models of
inflammation [49]. Of note, physiological concentrations
of the microbial metabolite and pan-HDAC inhibitor
butyrate specifically suppress IL-6, IL-12 and nitric oxide
production in gut macrophages suggesting that HDAC
inhibition may serve to limit autoinflammatory responses
to commensal microbes [13]. While Hdac3/ murinewww.sciencedirect.com macrophages display reduced inflammatory cytokine pro-
duction [50], selective deletion of HDAC3 in intestinal
epithelial cells alters intestinal architecture and increases
sensitivity to experimentally induced colitis [51]. In
addition, genetic or pharmacological disruption of
HDAC6 has recently been shown to enhance IL-10
production by activated macrophages via a mechanism
involving hyper-accumulation of acetylated a-tubulin
[52]. Defining the tissue- and cell-specific functions of
individual HDACs, coupled with development of iso-
form-selective HDAC inhibitors [53], will be needed to
discover optimal therapeutic strategies for targeting this
class of chromatin modulators.
Proteins that recognize differentially modified histones
and transcription factors to effect changes in cell state
may themselves be promising points of intervention. For
example, the BET (bromodomain and extra terminal)
family member BRD4 associates with the master regu-
lator of inflammatory cytokine production NF-kB follow-
ing acetylation at Lys310 [54]. Disrupting this interaction
with the small-molecule pan-BET inhibitor I-BET762
suppresses inflammatory cytokine production by macro-
phages and protects mice from bacteria-induced sepsis
[55]. In addition, inhibiting BRD4 with I-BET762 or (+)-
JQ1 is protective in murine models of demyelinating
disease by suppressing development of TH1 and
TH17 cells [56,57], which are inflammatory CD4
+ T cell
lineages that produce IFNg and IL-17A, respectively.
Future perspectives: emerging targets from
other protein classes
The success of biopharmaceuticals has validated modu-
lation of cytokine function as a therapeutic approach in
autoimmune/autoinflammatory disorders. However, there
are clear examples (e.g., IL-10 supplementation and
IL-17A blockade in CD [27,41]) where manipulation of
individual cytokines has been ineffective, and studies of
the genetics and physiology of these disorders has ident-
ified many intracellular proteins that contribute to disease
pathogenesis. A desire to overcome these challenges has
renewed interest in the historically productive approach of
regulating cytokine networks with small molecules.
To date, small-molecule regulation of cytokine function
has primarily focused on established targets like kinases
and transcriptional regulators. However, recent studies
are pointing to other protein classes as targets for treating
autoimmune/autoinflammatory disorders. Components of
the ubiquitin-proteasome system (e.g., TNFAIP3, which
encodes the ubiquitin modifying enzyme A20) are critical
for cytokine and pathogen receptor signaling, and have
been linked to IBD, SLE, RA and type 1 diabetes by
genetics [19]. In addition, the discovery of risk- and
protective alleles for IBD in CARD9 exons suggests that
scaffolding proteins may likewise be useful points of
intervention [10]. Although traditional drug discoveryCurrent Opinion in Chemical Biology 2014, 23:23–30
28 Molecular immunologyhas little experience with many emerging classes of
targets, recent innovations in small-molecule science
(e.g., targeted protein degradation [58], fragment-based
ligand discovery [59], and DNA-encoded synthesis [60])
suggest that significant advances in this field will be
forthcoming.
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